These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37068396)

  • 1. Current therapy and drug resistance in metastatic castration-resistant prostate cancer.
    Cai M; Song XL; Li XA; Chen M; Guo J; Yang DH; Chen Z; Zhao SC
    Drug Resist Updat; 2023 May; 68():100962. PubMed ID: 37068396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
    Ruiz de Porras V; Font A; Aytes A
    Cancer Lett; 2021 Dec; 523():162-169. PubMed ID: 34517086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    Bieńkowski M; Tomasik B; Braun M; Jassem J
    Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
    Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    Adashek JJ; Jain RK; Zhang J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors for prostate cancer.
    Longoria O; Beije N; de Bono JS
    Semin Oncol; 2024; 51(1-2):25-35. PubMed ID: 37783649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
    Labriola MK; Atiq S; Hirshman N; Bitting RL
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
    Sarwar S; Morozov VM; Purayil H; Daaka Y; Ishov AM
    Cell Death Dis; 2022 Oct; 13(10):868. PubMed ID: 36229449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].
    Heidegger I; Becker C; Tsaur I; Todenhöfer T;
    Urologe A; 2022 Feb; 61(2):187-192. PubMed ID: 35013792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Xu C; Mao S; Jiang H
    Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors.
    Roy S; Saad F
    Curr Opin Support Palliat Care; 2022 Dec; 16(4):223-229. PubMed ID: 36349381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
    Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
    Maughan BL; Antonarakis ES
    Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.